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Protecting the
Confidentiality of
Health Information
As the use of information technology spreads, concerns about the confidentiality of health information
increase. The public has become aware that much personal information is widely available and beyond the
control of the individual. Medical records, which often
contain personal and sensitive information, seem particularly vulnerable. In today’s health care marketplace, a
multitude of entities—managed care companies, retail
pharmacies, employers, and researchers—may have
access to personally identifiable health information.
Many policymakers have taken note of these concerns
and have called for federal legislation to protect the
confidentiality of health information, yet consensus on
how best to craft legislation remains elusive. Certain to be
contentious and complex, federal legislation would affect
numerous stakeholders. Many consumer and physician
groups argue that proposed legislation does not go far
enough to maintain the trust between physicians and
patients, thereby jeopardizing the quality of care delivered. Moreover, some consumer groups are concerned
about how health information is currently being used
beyond the realm of health care (for example, for law
enforcement activities or employment decisions). Therefore, they call for strict limits on its use. At the same time,
those who use health information to deliver, finance,
research, track, and evaluate health care-related services
worry that legislation will impede their ability to share
information and, therefore, make less information available for important health-related evaluation (such as
outcomes analysis, performance measurement, research,
and public health activities). Indeed, these users of
information believe there is a major disconnect between
demands for greater accountability in the health care
system and demands for privacy rights.
The Forum recently distributed a comprehensive
background paper on the confidentiality of health
information, prepared by Lise Rybowski. This Forum
session will concentrate on three of the key issue areas
raised in that paper: controlling access to health information, conducting research, and preempting state laws.

THE IMPETUS FOR LEGISLATION
A combination of factors has led to the call for a
legislative solution to protect the confidentiality of

health information. The most obvious stimulus is the
passage of the Health Insurance Portability and Accountability Act of 1996 (HIPAA), which effectively
set a deadline for Congress to act to protect personal
privacy. HIPAA required the secretary of health and
human services to make recommendations to Congress,
in consultation with the National Committee on Vital
and Health Statistics (NCVHS), on ways to protect
individually identifiable information and to establish
penalties for wrongful disclosure of personal health
information. The secretary presented those recommendations in September 1997; Congress now has until
August 1999 to enact a privacy law. If Congress fails to
act, the secretary is directed to promulgate regulations
within 42 months of HIPAA enactment (by February
21, 2000) relating to the privacy of health information
transmitted in connection with specified electronic
transactions.
HIPAA also contains administrative simplification
requirements designed to facilitate standardized,
electronic transmission of certain administrative and
financial health-related transactions. In fact, the privacy
provisions were included in HIPAA due to concerns
about the administrative simplification provisions.
DHHS is now in the process of issuing a series of
proposed regulations related to administrative simplification standards. Since May, the department has released
regulations relating to a uniform electronic health care
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claim (and other common administrative transactions),
unique identifier numbers for health care providers and
employers, and security standards for electronic health
data. In releasing the security regulations on August 11,
Secretary of Health and Human Services Donna Shalala
said that, while the standards are crucial, they are “not
enough.”1 In addition, she called for new legal protections
to safeguard the privacy of medical records in all forms.
One administrative simplification standard that has
yet to be released has generated tremendous controversy
and drawn sharp criticism from medical and privacy
advocates.2 Under HIPAA, DHHS is required to adopt
a unique health identifier number for each American.
The Clinton administration has said no proposal for
patient identifier numbers will be implemented until
privacy protections have been put in place. According
to DHHS officials, the timetable and substantive
requirements of HIPAA envisioned that federal privacy
protections would be in place at the same time the
transactions standards, standard identifiers, and system
security measures were implemented. If Congress fails
to enact a privacy law by August 1999, HIPAA requires
DHHS to issue regulations to protect the confidentiality
of information transmitted in connection with the
standardized transactions described in the law. These
regulations would have to be finalized by February
2000, before the effective date of the uniform data
standards.
Other factors that increase pressure for legislative
action include:








The notable progress of information technologies
over the last several years and the corresponding
increase in the usefulness and ubiquity of health
care data.
Growing awareness of the use of personal medical
data by various health care corporations for commercial advantage.
The growth of managed care, which has greatly
increased the number of entities that have access to
personal health information and, in turn, has accentuated concerns about privacy among both clinicians
and patients, particularly with respect to ways that
information may be used to create barriers to care
and coverage.
International pressures centered around a European
Union directive, effective October 1998, that prohibits member nations from disseminating information to organizations outside the country that do not
provide an adequate degree of privacy protection.

PENDING LEGISLATION
In response, Congress has stepped up its efforts to
enact privacy legislation. All of the major patient
protection bills pending in Congress contain confidentiality provisions. All would give individuals the right to
inspect and copy their medical records, except in
special circumstances. For example, a Senate GOP bill
(S. 2330), a bill introduced by Sen. Edward M. Kennedy (D-Mass.) and Rep. John D. Dingell (D-Mich.) (S.
1890/H.R.3605), and one sponsored by Sen. John H.
Chafee (R-R.I.) (S. 2416) contain broad requirements
for plan-associated health professionals and facilities to
post their confidentiality practices and to establish
appropriate safeguards to protect the confidentiality of
individually identifiable information. The bills do not
define these practices and safeguards.
The House Republican-crafted Patient Protection
Act of 1998 (H.R. 4250) contains more detailed provisions relating to medical records confidentiality. Under
the bill, “any person who maintains protected health
information may disclose the information to a health
care provider or a health plan for the purpose of permitting the provider or plan to conduct several health care
operations.” Health care “operations” are defined as
services, provided directly by or on behalf of a health
plan or health care provider or by its agent, for any of
the following purposes: (a) Coordinating health care,
including health care management of the individual
through risk assessment, case management, and
disease management. (b) Conducting quality assessment and improvement activities, including outcomes
evaluation, clinical guideline development and improvement, and health promotion. (c) Carrying out
utilization review activities, including precertification
and preauthorization of services, and health plan
rating activities, including underwriting and experience rating. (d) Conducting or arranging for auditing
services.

Critics have charged that the term “health care
operations” is so broad it could apply to anything,
including the transfer of patient information to companies marketing new drugs.3 Moreover, privacy advocates want the confidentiality provisions to be considered separately from the broader patient protection bill.
Health care industry representatives disagree, stating
that the House-passed bill achieves a balance between
consumers’ concerns over the confidentiality of health
information and their demands for high quality, affordable health care services.4
While the fate of this broad legislation remains
uncertain, several proposals focused exclusively on
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medical records confidentiality are circulating in
Congress. Sens. James M. Jeffords (R-Vt.) and Christopher T. Dodd (D-Conn.) have introduced the Health
Care Personal Information Nondisclosure Act of 1998
(S. 1921); and Sens. Patrick J. Leahy (D-Vt.) and
Kennedy have put forward the Medical Information
Privacy and Security Act (S. 1368); Sen. Robert F.
Bennett (R-Utah), who sponsored legislation during the
last session of Congress, is also drafting a bill that is
expected to be introduced this fall.
In the House, Reps. Christopher R. Shays (R-Conn.)
and Thomas M. Barrett (D-Wis.) have introduced the
Consumer Protection and Medical Record Confidentiality Act of 1998 (H.R. 3900), Rep. Jim McDermott (DWash.) has introduced the Medical Privacy in the Age
of New Technologies Act of 1997 (H.R. 1815), and Rep.
Gary A. Condit (D-Calif.) sponsored the Fair Health
Information Practices Act of 1997 (H.R. 52).

For instance, the Jeffords bill would require that
employers, health plans, and, under certain circumstances, providers obtain a single authorization to
disclose an individual’s protected health information for
purposes of treatment, payment, and health care operations.6 A separate authorization would be required for
other purposes, including “for disclosure with intent to
sell, transfer, or use protected health information for
commercial advantage.” The Shays bill would not
require a first-level authorization for treatment, payment, and certain health care operations. In contrast, the
Leahy bill would generally prohibit the disclosure of
protected health information without first obtaining an
individual’s authorization, except in limited circumstances. It would apply to each release of medical
information including re-releases. Furthermore, the
Leahy bill would allow patients to pay for treatment
themselves in order to avoid disclosure of personal
health information.

The differences in the bills highlight some of the
most contentious issues:

Research






What are the appropriate uses of personally identifiable information? To what extent can personally
identifiable information be disclosed without patient
authorization? For what purposes and under what
conditions?
Should federal regulations be applied to both federally and nonfederally funded researchers that use
personally identifiable data?
How broad should federal preemption of state laws
pertaining to confidentiality be?

Consent
All of the bills pending in the House and the Senate
would require, as a general rule, patient consent prior to
disclosure. The bills then set forth specific situations
and conditions, which vary from bill to bill, under
which information could be disclosed without consent.
The standards for disclosure for law enforcement
activities, in particular, vary widely.
Most bills would establish a two-tiered authorization
process. That is, they would allow health care entities to
require individuals to provide a first level of authorization for certain uses of personal health information as a
condition to receiving care or providing payment.5 After
this requirement had been met, a second level of
authorization would be required for disclosures not
related to treatment or payment, and individuals would
be permitted to refuse to consent to disclosures without
suffering adverse consequences.

The bills differ in their treatment of federally and
privately funded research and in their reliance on the
current Institutional Review Board (IRB) system. The
Leahy, Condit, and McDermott bills would require
approval by IRB for federally funded and nonfederally
funded research. Consistent with current federal regulations, the bills would permit the IRB to waive the
informed consent requirement if the potential benefit of
research outweighed the privacy interest of the individual. The Shays bill would permit disclosure to health
researchers if the disclosure were “reviewed by a
committee, board, or informal organization in accordance with confidentiality standards specifying permissible and impermissible uses of the information.”
The Jeffords bill would permit protected health
information to be disclosed to a health researcher who
obtains the data under the following circumstances:
(1) from federally funded projects or institutions that
have assurances on file with the Office of Protection
of Human Subjects at the National Institutes of Health
in compliance with rules specified by the federal
government; (2) in conformance with rules promulgated by the Food and Drug Administration for new
product trials; or (3) if the research is privately funded
human subject research.

The bill notes that there are currently no specific
procedures in place for the third classification of
research. The bill would provide for the Senate Committee on Labor and Human Resources to await the
recommendations of the secretary of health and human
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services, after reviewing the commissioned General
Accounting Office study on confidentiality and the
National Bioethics Advisory Commission’s report, to
determine appropriate confidentiality procedures for
privately funded human subject research.

Federal Preemption
The bills generally differ on whether or not to
establish a floor or ceiling for federal standards. The
Jeffords, Condit, and Shays bills generally would
preempt most state laws except those pertaining to
mental health and public health activities. The Leahy
and McDermott bills would not preempt any state laws
that provide a greater level of protection for personally
identifiable health information. The latter position is
generally consistent with the recommendations presented to Congress by DHHS.

THE FORUM SESSION
The Forum session will focus on the key issues
raised by the background paper and provide an opportunity for the various stakeholders to discuss the policy
implications of the options currently under consideration. In the interest of keeping the discussion focused,
particular emphasis will be placed on the three topics
identified earlier: controlling access to health information, conducting research, and preempting state laws.
Don Detmer, M.D., university professor of health
policy at the University of Virginia, will provide an
overview of the issues that must be resolved and some
of the options available to legislators, regulators, and
the health care industry. As chairman of the Secretary’s
National Committee on Vital and Health Statistics, Dr.
Detmer has been closely involved in providing guidance to DHHS regarding privacy and administrative
simplification requirements. As a researcher and
physician, he can also provide insight into how health
information is currently used. Dr. Detmer also maintains a surgical practice, co-directs the Virginia Health
Policy Center, and serves as chairman of the Board of
Health Care Services of the Institute of Medicine of the
National Academy of Sciences and of the board of
Vhita, a company committed to personal computerbased records.
Because of the large number of stakeholders involved in this issue and the desire to provide an opportunity for a variety of perspectives to be heard, following Dr. Detmer’s comments, the session will be conducted as a roundtable discussion with several knowl-

edgeable participants at the table. Key issues and
questions will be discussed by invited commentators as
well as by participants in the Forum’s audience. Invited
discussants include the following:
Jerry Avorn, M.D., an associate professor of
medicine at Harvard Medical School and chief of the
division of pharmacoepidemiology and pharmacoeconomics at Brigham and Women’s Hospital in
Boston, will discuss the research community’s concerns
as they relate to data privacy, including the use of IRBs
and the distinction between personally identifiable and
nonidentifiable data for research purposes. An internist,
geriatrician, and pharmacoepidemiologist, Dr. Avorn
has focused his research efforts on medication use, with
particular reference to elderly patients and chronic
disease. Dr. Avorn currently serves as president of the
International Society for Pharmacoepidemiology.
A.G. Breitenstein, director of the Justice Resource
Institute’s Health Law Institute in Boston, will discuss
the need to improve patient confidentiality and medical
privacy. As an attorney, Ms. Breitenstein provides
direct legal representation to individuals infected with
HIV and youth at high risk for becoming HIV infected.
She has been working on confidentiality issues for the
past three years and most recently was asked to testify
before Congress and NCVHS about various legislative
proposals now pending. She serves as a resource to
several national and state organizations, including the
National Resource Council and the Massachusetts Medical Society, as they develop policy regarding the
confidentiality of medical records.
Deborah Hammond, M.D., vice president of
medical management systems support for Prudential
HealthCare (PHC), will discuss insurance management
issues and how proposed legislation might affect the
plan’s ability to conduct utilization review, measure the
performance of providers, or otherwise do business. In
addition, she will discuss the company’s current practices regarding the confidentiality of health information
and demands for this information from outside parties
and how Prudential responds to these requests. Dr.
Hammond is a physician leader in PHC, where she has
served in a variety of capacities since 1986. Her current
areas of responsibility include oversight of utilization
management, quality improvement, pharmacy services,
data capture and data warehousing, information delivery, and provider connectivity as well as interfacing
with other system support areas, claims/encounter
processing, provider network support, member service
support, and sales and marketing.
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Chris Koyanagi, legislative policy director for the
Bazelon Center for Mental Health Law, will discuss the
concerns of the mental health community. With over 25
years of experience as a government affairs specialist,
Ms. Koyanagi has a substantial understanding of both
mental health policy and the federal policy process. In
her role as director of the legislative agenda for the
Bazelon Center, a legal advocacy organization concerned about the rights of persons with severe mental
illness, she supervises federal government relations and
state initiative staff.
Harriet Pearson, director of public affairs for IBM
Corporation, will discuss the perspective of large, selfinsured employers. She will address how employers use
health information and what safeguards are in place to
protect against discrimination. Ms. Pearson directs
IBM’s involvement in the areas of privacy, health care,
workplace policy, and environmental and energy public
policy. Since 1997, she has led IBM’s work on privacy
policy issues, focusing particularly on Internet privacy
and medical records issues
Joy Johnson Wilson, federal affairs counsel and
director of the Health Committee at the National
Conference of State Legislatures (NCSL), will discuss
state laws in the area of medical records confidentiality
and the implications of federal preemption. NCSL
represents the legislatures of the 50 states, its commonwealths, territories, and the District of Columbia; its
Health Committee guides the development of the
organization’s policy on all health care issues. As
director, Ms. Wilson, who has been with NCSL since
1978, follows health care reform at both the state and
federal levels, including privacy, Medicaid, and other
health initiatives of importance to state legislatures.

KEY QUESTIONS
Controlling Access to Health Information






Who should have access to individually identifiable
information?










Should employers (including self-insured employers) have special limits placed on their access? If so,
what are the implications for their ability to make
coverage decisions or ensure accountability and
efficiency?

Under what circumstances should authorization
from the patient be required for disclosures of
personal health information? Should there be
stricter requirements for certain types of information, for example, mental health records?
What are the implications of requiring individual
authorizations for information disclosure?
What is the value of informed consent?
What role should individuals have in determining
who can see their information?
Should consent be obtained from individuals to
transfer personal health information to other entities,
such as retail pharmacies?
How prevalent is the sale, transfer, or use of personally identifiable health information for commercial
advantage?

Conducting Research








How much access should they have? For what
purposes?
Who should control that access and how?

What are common applications of personal health
information? Of these, what should be permitted or
prohibited?

What activities should be defined as “research”? For
example, clinical trials, outcomes research, disease
management?
How can a federal privacy law create incentives for
researchers to use health data that are not personally
identifiable?
In what instances are personally identifiable data
necessary to conduct research?
If researchers were required to obtain informed
consent from research subjects, what would be the
implications?
How well does the current IRB process work to
protect privacy?
Should regulations be applied to both federally and
nonfederally funded researchers? That is, should
IRB approval be required prior to receiving identifiable information?

Preempting State Laws



Should federal legislation set a floor of minimum
standards for privacy protection, which individual
states could exceed, or should it establish a ceiling
of uniform standards that must be met by all parties
but can not be exceeded by the states?
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What are the implications of a federal “floor”
approach for national health plans, pharmaceutical
companies, and big hospital systems that operate
across state laws?
Under a broad federal preemption, what would be
the implications for states with stricter requirements
on the books?
Should certain state laws, such as mental health
laws, be exempt from preemption? If so, what are
the implications of isolating mental health information from an individual’s medical record?
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